|Bid||158.06 x 900|
|Ask||158.80 x 1400|
|Day's range||157.44 - 158.80|
|52-week range||150.11 - 183.35|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||33.16|
|Earnings date||20 Jul 2023|
|Forward dividend & yield||4.76 (3.01%)|
|Ex-dividend date||22 May 2023|
|1y target est||179.71|
Alkermes (ALKS) receives final award in arbitration proceedings with partner Janssen. It also raises its financial outlook for 2023.
A reasonably small amount of money can go a long way when it's invested in industry-leading businesses.
NEW BRUNSWICK, N.J., June 06, 2023--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Thursday, July 20th to review second-quarter results. Joaquin Duato, Chairman of the Board and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call.
(Bloomberg) -- Kenvue Inc. looked like a winner following its May spinoff from Johnson & Johnson in the year’s biggest IPO. But just a few weeks after the stock’s initial surge, Wall Street is urging investors to avoid the shares.Most Read from BloombergPGA Tour Bows to Saudi Rival in Shock Combination With LIV GolfUkraine Dam Blast Blamed on Russia Tips War Into New PhaseGeorge Santos Loses Bid to Shield the People Who Guaranteed His $500,000 BailSEC’s Coinbase Lawsuit Heralds Deepening US Cryp
Johnson & Johnson (JNJ) closed at $158.32 in the latest trading session, marking a +0.86% move from the prior day.
Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting. Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022. Its patents begin to expire this year, opening the door to a cheaper biosimilar entering the market, and raising expectations that the company would need to lower the $13,000 per month price of Stelara.
Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns.
Johnson & Johnson (NYSE: JNJ) is one of the best dividend stocks on the planet. The healthcare behemoth has increased its dividend each year for over six decades, putting it in the super-elite class of Dividend Kings. The company currently offers a roughly 3% dividend yield, which is almost double that of an S&P 500 Index Fund (recently around 1.6%).
These time-tested businesses produce reliable cash flows that they're committed to sharing with investors.
If you can't beat the S&P 500 by picking individual stocks, owning an S&P 500 index fund and at least earning market returns is a smart move. Not just any dividend-paying stocks, mind you, but those that can grow their dividend payments consistently. Hartford Funds and Ned Davis Research have been tracking the average annual total returns of companies in the S&P 500 by dividend policy.
Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to their...
These two stocks look like the best options among the Dow Jones Industrial Average's 30 components right now.
LAVA's (LVTX) shares soar as partner J&J (JNJ) selects a lead candidate for development in clinical studies for cancer.
Many high-quality dividend stocks currently yield around 3%, nearly double that of the S&P 500. American Tower's dividend yield is currently over 3%, a historically high rate for the data-infrastructure real estate investment trust (REIT). The company has an exceptional track record of paying dividends.
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
It could take years before Nano-X proves there's strong demand for its devices, and even longer to reach profitability.
The Dow Jones Industrial Average consists of 30 of the most established businesses in the world. Thus, it shouldn't be a surprise to learn that many of the components that belong to this index have decades of dividend growth to their credit. Here are two Dow Jones stocks with more than a century of dividend growth between them to consider buying this month.
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.
Based on a 58-year track record as CEO of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), it's safe to say Warren Buffett knows a thing or two about investing. As of this past weekend, he'd overseen a greater than 3,900,000% return in his company's Class A shares (BRK.A) since taking the reins at Berkshire. What follows are three Warren Buffett stocks that stand out as screaming buys in June.
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
(Bloomberg) -- Eli Lilly & Co.’s third straight month of gains has helped it become the largest pharmaceutical company in the world by market value, surpassing Johnson & Johnson.
(Reuters) -Johnson & Johnson on Wednesday faced the first trial in almost two years over claims that asbestos in its baby powder and other talc products causes cancer, as it seeks to settle thousands of similar cases in bankruptcy court. Emory Hernandez, 24, says he developed mesothelioma, a deadly cancer, in the tissue around his heart as a result of exposure to J&J's talc products beginning when he was a baby.
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
In the latest trading session, Johnson & Johnson (JNJ) closed at $154.37, marking a +0.01% move from the previous day.